News Santhera's DMD drug poised for wider rollout in Germany Santhera has agreed pricing and reimbursement for its Duchenne muscular dystrophy drug Agamree with German health funds representing 90% of patients.
Market Access NICE contribution to the cost per QALY threshold debate? Leela Barham sets out some wider context to the latest blog from NICE on the cost-effectiveness threshold used by the agency and highlights the opportunity for stakeholders to build their c
R&D Life Sciences Industry Report - Biologics and Generics The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
News Medicare price negotiations 'will continue under Trump' President Trump will continue Medicare drug pricing negotiation but intends to look for improvements to the scheme according to CMS.
News Vaccines dominate questioning at RFK Jr's first hearing Robert F Kennedy Jr's first confirmation hearing was a fractious affair, marked by tough questions about his prior anti-vaccine stance.
News Lyfegen partners EVERSANA on pricing, access resource Lyfegen and EVERSANA have joined forces to help pharma companies navigate an increasingly complex global drug pricing and access environment.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.